Superior detection vs White Light Cystoscopy alone

BLC® with Hexvix® allows you to detect bladder cancer missed under White Light Cystoscopy alone1,2,3

Improved management and patient outcomes vs White Light Cystoscopy alone
key point 1
More complete TURBT procedures4
key point 2
Reduced recurrences3,5,6
key point 3
Detects more recurrent cancer when used in flexible cystoscopy2
key point 4
Hexvix® should be used for the first TURBT and for all intermediate and high-risk NMIBC patients, during surgical treatment and surveillance/follow-up7,8,9
key point 5
Most patients found Hexvix® worthwhile10
key point 6
Hexvix® is cost effective in the treatment and management of NMIBC8

What is Hexvix®

Hexvix® is a drug that is taken up by cancer cells in the bladder making them glow bright pink during BLC®.11

By making cancer cells glow bright pink under BLC®, Hexvix® improves the detection of NMIBC

  • Detects lesions missed under WLC alone1,2,3
  • Detects more lesions than WLC alone1,2,3

 

 

Better visualization leads to:

  • More patients with bladder cancer being identified1,2,3
  • More complete TURBT procedures4
  • Reduced recurrences3,5,6
  • Increased time to recurrence12

 

Hexvix® can be used with a:

a

Hexvix® Key Points

1. Burger M et al. European Urology 2013; 64(5):846-854.<br>2. Daneshmand S et al. The Journal of Urology 2018; 199:1158-1165.<br>3. Stenzl A et al. The Journal of Urology 2010; 184:1907-1914. 1. Burger M et al. European Urology 2013; 64(5):846-854.<br>2. Daneshmand S et al. The Journal of Urology 2018; 199:1158-1165.<br>3. Stenzl A et al. The Journal of Urology 2010; 184:1907-1914.

key point 1

1. Burger M et al. European Urology 2013; 64(5):846-854.<br>4. Hermann G et al. BJU International 2011; 108:E297-E303.<br>5. Gallagher K et al. World J Urol 2017; 35:1871-1877.<br>6. Geavlete B et al. BJU Int 2012; 109:549-556. 1. Burger M et al. European Urology 2013; 64(5):846-854.<br>5. Gallagher K et al. World J Urol 2017; 35:1871-1877.<br>6. Geavlete B et al. BJU Int 2012; 109:549-556. 4. Hermann G et al. BJU International 2011; 108:E297-E303.

key point 2

7. Daneshmand S et al. Nat Rev Urol 2014; 11:589-596. 10. Smith AB et al. BJU International 2018; 123:35-41.

key point 3

Indication Hexvix®

Hexvix® indication11: Europe

Hexvix Blue Light fluorescence cystoscopy is indicated as an adjunct
to standard White Light Cystoscopy to contribute to the diagnosis and
management of bladder cancer in patients with known or high suspicion of bladder cancer.

 

SmPC

a

Superior Detection versus WLC Alone

Hexvix® detects bladder cancer missed under White Light Cystoscopy alone3,4,5

Hexvix® can
be used during
surgical treatment
and surveillance
/follow-up

4. Hermann G et al. BJU International 2011; 108:E297-E303.

a

3. Stenzl A et al. The Journal of Urology 2010; 184:1907-1914.

a

In 25%
of patients at least 1
additional lesion was
found with Hexvix®3

Hexvix® detects patients with CIS that would be missed under WLC alone2

CIS simply
isn’t visible
in half of cases
observed13

2. Daneshmand S et al. The Journal of Urology 2018; 199:1158-1165.

a

2. Daneshmand S et al. The Journal of Urology 2018; 199:1158-1165.

a

The presence of CIS
more than doubles the risk of
progression14

Hexvix® cystoscopy identified CIS patients who were thought to be CIS free after WLC1

Improved Management and Patient Outcomes vs White Light Cystoscopy Alone

Hexvix® can be used during surgical treatment and surveillance/follow-up11

4. Hermann G et al. BJU International 2011; 108:E297-E303. Hexvix after complete WLC TURBT

 

4. Hermann G et al. BJU International 2011; 108:E297-E303. a

In detecting additional tumors, Hexvix® significantly modified the risk categories of patients and improved the related postoperative intravesical instillation treatment15

16. Babjuk M et al. Eur Urol 2019; 76(5):639-657. a

Hexvix® TURBT procedures led to reduced recurrence rates versus WLC TURBT alone 3,5,15

Reduced short and long-term
recurrence rates in Hexvix® patients3,5,15

 

Significantly lower
recurrence rates when Hexvix® is used in a TURBT procedure3,5,15

 

 

5. Gallagher K et al. World J Urol 2017; 35:1871-1877. a

This message is only to be used if specifically requested by the Physician and should not be proactively communicated

  • The above is to avoid having Hexvix® niched for use in high-risk patients, when it can benefit intermediate risk patients as well
  • Earlier detection will lead to better patient outcomes

Hexvix® led to increased time to recurrence12

Patients remained on average an additional 7 months tumor free when Hexvix® was used versus WLC alone12

a

Hexvix® can be used during surgical treatment and surveillance/follow-up

Hexvix® guided TURBT demonstrated to be an independent predictor for improved survival after radical cystectomy19

20. Renninger M et al. World J Urol 2019. 20. Renninger M et al. World J Urol 2019.

Hexvix guided turbt demonstrated to be an independant predictor

CSS: Cancer Specific Survival; OS: Overall Survival.

Hexvix® Usage

Hexvix® should be used for the first TURBT and for all intermediate and high-risk patients, during surgical treatment and surveillance/follow-up7,8,9

How is Hexvix® used

Recommended use cases7,8,9

a

*primarily for referred patients
**consensus on frequency was not reached